NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: AMANTA · data 2026-11-01
Amanta Healthcare Limited
In plain words
Price: 22.1% below its 52-week high of ₹209.95.
Delivery: 52.4% of traded shares were kept for delivery over the last 10 sessions, against 52.6% over the last 60.
Latest results: a net profit of ₹3 cr for the quarter ended Jun 2026 (-5.7% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹291 cr |
| Net profit (last 12 months) | ₹15 cr |
| Sales growth, 3 years (yearly) | 3.5% |
| Profit growth, 3 years (yearly) | — |
At a glance
Promoters 63.8% (+0.2 pts in a year), pledged 0.0%, institutions 12.3%.
P/E 43.3, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 9.4%, ROCE 11.5%, operating margin 14.0%: how much profit it earns on the money it uses.
Debt/equity 1.11, Profit growth — and sales growth 3.5% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
None flagged by these rules.
- Slow sales growth (3.5% a year over 3 years).
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
AMANTA Q1 FY27 results (standalone figures, as filed on NSE).
Revenue was ₹68.8 crore, up 5.3% YoY and down 10.6% QoQ.
Net profit was ₹3.31 crore, down 5.7% YoY and down 40.1% QoQ.
Operating margin was 21.1% (22.8% a year ago).
EPS was ₹0.85, down 5.6% YoY and down 47.2% QoQ.
AMANTA के Q1 FY27 नतीजे (स्टैंडअलोन आंकड़े, NSE पर दाखिल)।
राजस्व: ₹68.8 करोड़; पिछले साल की तुलना में 5.3% की बढ़त, पिछली तिमाही की तुलना में 10.6% की गिरावट।
शुद्ध मुनाफ़ा: ₹3.31 करोड़; पिछले साल की तुलना में 5.7% की गिरावट, पिछली तिमाही की तुलना में 40.1% की गिरावट।
ऑपरेटिंग मार्जिन: 21.1% (एक साल पहले 22.8%)।
EPS: ₹0.85; पिछले साल की तुलना में 5.6% की गिरावट, पिछली तिमाही की तुलना में 47.2% की गिरावट।
AMANTAના Q1 FY27 પરિણામો (સ્ટેન્ડઅલોન આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹68.8 કરોડ; ગયા વર્ષની સરખામણીએ 5.3% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 10.6% ઘટાડો.
ચોખ્ખો નફો: ₹3.31 કરોડ; ગયા વર્ષની સરખામણીએ 5.7% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 40.1% ઘટાડો.
ઓપરેટિંગ માર્જિન: 21.1% (એક વર્ષ પહેલાં 22.8%).
EPS: ₹0.85; ગયા વર્ષની સરખામણીએ 5.6% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 47.2% ઘટાડો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
11/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Too few delivery days to compare delivery % (0 of 10); shares delivered not comparable (0 of 12); 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 6/15: 0 insider buy days (promoter group among them) and 1 SAST acquisition day in 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Insider ● Results
- 8 Oct 26Insider SAST disclosure: Kirit Amablal Desai acquired 1,50,400 shares -9.5% next session
- 5 Aug 26Results Q1 FY27 results: profit −5.7% YoY -0.1% next session
- 29 May 26Results Q4 FY26 results: net profit ₹5.5 cr -8.0% next session
- 29 May 26Results Q3 FY26 results: net profit ₹4.6 cr -8.0% next session
- 27 May 26Results Q2 FY26 results: net profit ₹1.2 cr -5.8% next session
- 19 May 26Results Results board meeting +0.4% next session
- 10 Feb 26Results Results board meeting +2.9% next session
- 11 Nov 25Results Results board meeting +2.2% next session
- 27 Sept 25Results Q1 FY26 results: net profit ₹3.5 cr +1.4% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (standalone)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹69 cr | ₹3 cr | -5.7% | 21.1% | 0.85 |
| Mar 2026 | ₹77 cr | ₹6 cr | — | 19.4% | 1.61 |
| Dec 2025 | ₹74 cr | ₹5 cr | — | 20.6% | 1.35 |
| Sept 2025 | ₹71 cr | ₹1 cr | — | 20.7% | 0.35 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 63.80% | 63.80% | 63.72% | 63.56% |
| Foreign institutions (FII) | 0.07% | 0.43% | 0.85% | 1.10% |
| Domestic institutions (DII) | 12.20% | 12.92% | 12.88% | 11.24% |
| Mutual funds | 5.12% | 5.33% | 5.09% | 3.99% |
| Retail investors | 11.33% | 10.09% | 9.13% | 9.10% |
| Number of shareholders | 12,319 | 12,612 | 15,222 | 16,181 |
Common questions
What was Amanta Healthcare Limited's latest quarterly profit?
Amanta Healthcare Limited reported a net profit of ₹3 cr for the quarter ended Jun 2026 (-5.7% on the same quarter a year earlier), on revenue of ₹69 cr.
How much do promoters hold in Amanta Healthcare Limited?
Promoters held 63.80% of Amanta Healthcare Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Amanta Healthcare Limited debt-free?
Its latest reported debt-to-equity ratio is 1.11, meaning borrowings are larger than shareholders' equity.
What is Amanta Healthcare Limited's P/E ratio?
About 43.3, based on the last 12 months' earnings and a price of ₹163.56 (data 2026-11-01).
What is the 52-week high and low of Amanta Healthcare Limited?
The 52-week high is ₹209.95 and the 52-week low is ₹92.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Amanta Healthcare Limited | ₹163.56 | ₹632 cr | 43.3 | — | 9.4% | 11.5% | 1.11 | +33.5% |
| Kilitch Drugs (India) Limited | ₹201.32 | ₹703 cr | 23 | — | 12.5% | 12.3% | 0.32 | +1.5% |
| Valiant Laboratories Ltd. | ₹128.4 | ₹695 cr | 43.5 | — | -1.2% | 0.2% | 0.15 | +48.6% |
| Hexagon Nutrition Limited | ₹54.11 | ₹664 cr | — | — | 17.7% | 18.7% | 0.14 | +12.1% |
| Wanbury Limited | ₹189.21 | ₹664 cr | 11.6 | — | 64.9% | 31.1% | 1.57 | -25.8% |
| Praveg Limited | ₹204.91 | ₹539 cr | — | — | -2.5% | 1.6% | 0.38 | -24.4% |
Compare AMANTA with KILITCH in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open AMANTA in NSE Scanner →